Valion Bio Profit Margin

Valion Bio posts a profit margin of 6328.21% as of June 2026. That compares with -1372.51% in the prior-year period — up 561.1% year over year. That is above the sector sector average of 13.16%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Valion Bio's profit margin was -1372.51%. The latest reading is 6328.21% — a 561.1% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

For its sector stocks, a profit margin near 13.16% is typical. Valion Bio's 6328.21% is higher that level. That is roughly 47973.8% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Valion Bio's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 6328.21% as of June 2026; use YoY and peer views to separate noise from signal.

Context for VBIO's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.16%), and (3) consistency with growth and profitability. This page covers the first two; Valion Bio's other metric pages and overview cover the third.